Validating Quality of Life Modules in Lymphoma
Research type
Research Study
Full title
An international field study for the reliability and validity of the Phase IV EORTC Quality of Life modules for patients with Hodgkin’s Lymphoma (EORTC QLQ-HL27), high-grade non-Hodgkin’s Lymphoma (EORTC QLQ-NHL-HG29), low-grade non-Hodgkin’s Lymphoma (EORTC QLQ-NHL-LG20), and Chronic Lymphocytic Leukaemia (EORTC QLQ-CLL17)
IRAS ID
235255
Contact name
Louise Enfield
Contact email
Sponsor organisation
Netherlands Comprehensive Cancer Organisation
Duration of Study in the UK
1 years, 11 months, 31 days
Research summary
The aim of the project is to test the reliability and validity of four specific questionnaires that have been developed to assess the quality of life of lymphoma and chronic lymphocytic leukaemia (CLL) patients involved in clinical trials.
The four specific questionaires have been developed to include symptoms, treatment related issues and any additional dimensions of quality of life specific to lymphoma and chronic lymphocytic leukaemia that are not sufficiently covered by the generic quality of life modules. The questionaires will be administered in combination with the generic EORTC QLQ−C30. The EORTC QLQ−C30 is a standardised questionnaire that has been developed by the European Organisation for Research and Treatment of Cancer (EORTC) that covers 30 mains symptoms and issues that may affect people with cancer.
Patients will not directly benefit from participating, but in the long term we hope we will be able to offer better quality of care for all patients, because we will gain information on the quality of life and (long term) complaints of these survivors.
REC name
London - City & East Research Ethics Committee
REC reference
18/LO/1154
Date of REC Opinion
19 Jul 2018
REC opinion
Favourable Opinion